Marker Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 8
- Market Cap
- -
- Introduction
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06552416
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸KU Cancer Center, KAnsas city, Kansas, United States
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- Conditions
- Pancreas Cancer
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06549751
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Conditions
- Hodgkin LymphomaHodgkin's Lymphoma, Relapsed, AdultNon Hodgkin LymphomaNon-Hodgkin Lymphoma, AdultNon-Hodgkin Lymphoma, RefractoryNon-Hodgkin Lymphoma, RelapsedHodgkin Lymphoma, Adult
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT05798897
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT04511130
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Moores Cancer Center at University of Californa San Diego, La Jolla, California, United States
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
- Conditions
- Platinum Sensitive Ovarian CancerOvarian Cancer
- Interventions
- Drug: Adjuvant (GM-CSF) AloneBiological: FRα peptide plus Adjuvant (GM-CSF)
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02978222
- Locations
- 🇺🇸
UAB Gynecology Oncology, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Cancer Center, Phoenix, Arizona, United States
🇺🇸Women's Cancer Research Foundation, Newport Beach, California, United States
- Prev
- 1
- 2
- Next
News
Lymphodepletion Enhances MAR-T Cell Therapy Efficacy in Lymphoma Patients, Marker Therapeutics Reports
Marker Therapeutics' Phase 1 APOLLO study shows lymphodepletion significantly improves expansion and persistence of MT-601 MAR-T cells in lymphoma patients, potentially enhancing anti-tumor activity.
FibroBiologics Opens New Houston Laboratory to Accelerate Fibroblast-Based Therapeutics Development
• FibroBiologics has unveiled a new 10,000-square-foot laboratory facility in Houston that will bring manufacturing operations in-house and accelerate development of fibroblast-based therapeutics for chronic diseases. • The expanded facility will increase the company's research capabilities, reduce reliance on external partners like Charles River Laboratories, and enable FibroBiologics to streamline its supply chain for cell therapy products. • With 240+ patents issued and pending, FibroBiologics plans to hire additional researchers to support its growing pipeline of candidates targeting multiple chronic disease indications using its proprietary fibroblast technology.
Marker Therapeutics' MT-601 Shows 78% Response Rate in Refractory Lymphoma Patients
• Marker Therapeutics' lead MAR-T cell therapy MT-601 (neldaleucel) demonstrated a 78% objective response rate in lymphoma patients who relapsed after anti-CD19 CAR-T therapy, with 44.4% achieving complete responses. • The company secured over $13 million in non-dilutive funding from CPRIT and NIH to support clinical programs for pancreatic cancer and lymphoma, while also raising $16.1 million through a private placement. • MT-601 showed a favorable safety profile with no immune-effector cell associated neurotoxicity syndrome and only one case of Grade 1 cytokine release syndrome reported in the Phase 1 APOLLO trial.
MAGEA4-Targeted Therapies Show Promise in Solid Tumors Beyond Synovial Sarcoma
Afamitresgene autoleucel (afami-cel; Tecelra) received FDA approval for unresectable or metastatic synovial sarcoma, marking the first engineered cell therapy approval for a solid tumor.